A phase III randomised, multicentre, international trial to determine the relation between dose and clinical activity of ST1571 in patients with unresectable or metastatic malignant gastrointestinal stromal tumours (GIST) expressing the KIT receptor tyrosine kinase (CD117).

 

Trial Summary:

Phase III randomised, multicentre international trial to determine the relation between dose and clinical activity of STI-571 in patients with unresectable or metastatic malignant gastrointestinal stromal tumors expressing the c-KIT receptor tyrosine kinase (CD117). Gastrointestinal stromal tumours are rare and highly resistant to standard chemotherapy and radiation. A new chemotherapy tablet, STI-571 (Glivec), has produced dramatic responses in people with this kind of cancer. This trial is comparing higher and lower doses of STI-571. Trials of STI-571 in other cancers are being planned around the world.

Supported By:

Novartis Pharmaceuticals Australia; Novartis International AG (Switzerland); European Organisation for Research and Treatment of Cancer (Belgium); AGITG

Eligibility:

Patients with unresectable or metastatic malignant gastrointestinal stromal tumors

Registration ID:

ACTRN12605000138684

Participation:

International

Australian Lead Group:

AGITG

Status:

Close out

Activation Date:

01/02/2001

Chairs:

John Zalcberg (Australia)

Contact:

eortc62005@ctc.usyd.edu.au